Pharvaris (NASDAQ:PHVS) President Sells $3,500,000.00 in Stock

Pharvaris N.V. (NASDAQ:PHVS) President Peng Lu sold 100,000 shares of Pharvaris stock in a transaction that occurred on Thursday, September 17th. The stock was sold at an average price of $35.00, for a total transaction of $3,500,000.00. Following the completion of the transaction, the president directly owned 64,953 shares in the company, valued at approximately $2,273,355. The trade was a 60.62% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Peng Lu also recently made the following trade(s):

• On Friday, September 11th, Peng Lu sold 15,000 shares of Pharvaris stock. The stock was sold at an average price of $40.13, for a total transaction of $601,950.00.
• On Tuesday, September 8th, Peng Lu sold 15,000 shares of Pharvaris stock. The shares were sold at an average price of $40.68, for a total transaction of $610,200.00.

Pharvaris Stock Down 6.1%

Shares of PHVS opened at $33.07 on Thursday. The company has a market cap of $2.16 billion, a price-to-earnings ratio of -10.84 and a beta of -2.33. Pharvaris N.V. has a twelve month low of $20.65 and a twelve month high of $43.25. The company has a 50 day moving average of $35.36 and a two-hundred day moving average of $31.93.

Pharvaris (NASDAQ:PHVS) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.06). On average, sell-side analysts expect that Pharvaris N.V. will post -3.12 EPS for the current year.

Institutional Trading of Pharvaris

Several large investors have recently added to or reduced their stakes in PHVS. Engineers Gate Manager LP acquired a new position in shares of Pharvaris in the second quarter valued at about $1,143,000. Amundi raised its stake in shares of Pharvaris by 61.4% in the second quarter. Amundi now owns 49,944 shares of the company’s stock worth $1,727,000 after purchasing an additional 18,992 shares during the last quarter. Moore Capital Management LP acquired a new stake in shares of Pharvaris during the second quarter worth about $1,522,000. Alyeska Investment Group L.P. boosted its position in Pharvaris by 225.5% in the second quarter. Alyeska Investment Group L.P. now owns 406,829 shares of the company’s stock valued at $14,068,000 after buying an additional 281,829 shares during the last quarter. Finally, Wellington Management Group LLP boosted its position in Pharvaris by 12.9% in the second quarter. Wellington Management Group LLP now owns 2,392,934 shares of the company’s stock valued at $82,748,000 after buying an additional 274,034 shares during the last quarter.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on PHVS shares. Wedbush upped their target price on Pharvaris from $42.00 to $50.00 and gave the company an “outperform” rating in a research report on Wednesday, September 9th. New Street Research set a $60.00 price target on Pharvaris in a research note on Friday, August 14th. Leerink Partners upped their price objective on shares of Pharvaris from $50.00 to $65.00 and gave the company an “outperform” rating in a report on Wednesday, September 9th. Citigroup reiterated a “market outperform” rating on shares of Pharvaris in a research note on Wednesday, September 9th. Finally, Morgan Stanley upped their price target on shares of Pharvaris from $46.00 to $62.00 and gave the company an “overweight” rating in a research note on Wednesday, September 9th. Thirteen research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $59.87.

About Pharvaris

Pharvaris N.V. is a biopharmaceutical company focused on developing oral therapies for hereditary angioedema (HAE), a rare genetic disorder characterized by recurrent episodes of swelling. The company is headquartered in Zug, Switzerland, and was founded in 2015 by former executives from Pharming Group.

Pharvaris’ lead investigational medicine is deucrictibant, an orally administered small-molecule bradykinin B2 receptor antagonist. The company is evaluating different formulations of deucrictibant for both on-demand treatment of HAE attacks and long-term prevention of attacks.